Drug Trial Radar · NCT06633419
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
Last checked: Nov 19, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Dec 18, 2024
Primary completion
Feb 12, 2025
Study completion May 13, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.
Conditions
- Healthy
Interventions
OpevesostatDrug
Administered via oral tablet per dosing regimen.
PrednisoneDrug
Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
Fludrocortisone acetateDrug
Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
CarbamazepineDrug
Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Area under the concentration versus time curve from 0 to hour 24 (AUC0-24) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 24 hours post-dose
- Maximum concentration (Cmax) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Time to Maximum concentration (Tmax) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Apparent terminal half-life (t1/2) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Apparent Clearance (CL/F) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
- Apparent volume of distribution during terminal phase (Vz/F) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion ( Site 0001)
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.